Scarica l'app Stockscreener
4.09
0.00%
0.00
Dopo l'orario di chiusura:
4.09
Precedente Chiudi:
$4.09
Aprire:
$4
Volume 24 ore:
199.03K
Relative Volume:
1.16
Capitalizzazione di mercato:
$154.82M
Reddito:
$147.12M
Utile/perdita netta:
$-33.88M
Rapporto P/E:
-8.512
EPS:
-0.4805
Flusso di cassa netto:
$-13.62M
1 W Prestazione:
-5.98%
1M Prestazione:
-12.23%
6M Prestazione:
-40.72%
1 anno Prestazione:
-41.65%
Intervallo 1D:
$4.00
$4.27
Intervallo di 1 settimana:
$4.00
$4.60
Portata 52W:
$3.625
$8.9799
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Nome
Lifecore Biomedical Inc
Settore
Telefono
(952) 368-4300
Indirizzo
3515 LYMAN BOULEVARD, CHASKA
Compare LFCR vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
4.09 | 154.82M | 147.12M | -33.88M | -13.62M | -0.4805 |
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 58.15B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.35 | 42.94B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.22 | 40.59B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.86 | 30.29B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
503.86 | 21.74B | 3.17B | 1.29B | 1.01B | 27.09 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2025-09-04 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2025-05-21 | Iniziato | William Blair | Outperform |
| 2024-09-05 | Iniziato | Craig Hallum | Buy |
| 2024-08-28 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2023-03-20 | Downgrade | Stephens | Overweight → Equal-Weight |
Mostra tutto
Lifecore Biomedical Inc Borsa (LFCR) Ultime notizie
Lifecore Biomedical to Participate at CPHI Global Conference - Yahoo Finance
Lifecore Strikes Tech Transfer Deal for Commercial Manufacturing of Major Pharma Company Injectable - Contract Pharma
Lifecore Biomedical Signs New Commercial Transfer Agreement for Marketed Injectable Product - Quiver Quantitative
A marketed injectable drug is expected to bring Lifecore revenue in 2028. - Stock Titan
LFCR Q2 2026 Earnings: Narrower Loss of -$0.19 Beats Estimates, Shares Dip 1.35%Revenue Guidance Update - vinanet.vn
Lifecore (LFCR) Results at a Glance: EPS Lands Above Forecast in Latest Trading; Session Move: Shares Rise 0.22% at the CloseEarnings Season Preview - vinanet.vn
Lifecore (LFCR) Earnings Reading: EPS Prints Above Forecast at the Close; After Results: Shares Move 2.42% Down on the DayGuidance Downgrade Alert - vinanet.vn
LFCR | Lifecore Biomedical, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Lifecore Biomedical Earnings Call Balances Growth and Strain - TipRanks
Lifecore (LFCR) Quarterly Scorecard: EPS Beats Its Estimate; The Stock Records a 1.83% Increase on the DayROA Comparison - vinanet.vn
Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript - AOL.com
Core Thesis Behind Lifecore Biomedical (LFCR): Monetizing Excess Capacity - Yahoo Finance
Avoiding Lag: Real-Time Signals in (LFCR) Movement - Stock Traders Daily
LFCR Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 16.59% EPS SurpriseAnalyst Coverage Count - vinanet.vn
Lifecore Biomedical (LFCR) Holds Above $4.50 Support as Shares Edge LowerSell Signal Alerts - vinanet.vn
LFCR Q2 2026 Earnings: Narrower-than-Expected Loss Offers Modest EncouragementGuidance vs Actual - vinanet.vn
Judge approves $3.75 million Lifecore investor settlement - Minnesota Lawyer
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update - marketscreener.com
Lifecore Biomedical, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Discipline and Rules-Based Execution in LFCR Response - Stock Traders Daily
Earnings call transcript: Lifecore Biomedical tops revenue view in Q2 2026 - Investing.com Canada
Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Transcript : Lifecore Biomedical, Inc., Q2 2026 Earnings Call, Aug 05, 2026 - marketscreener.com
Lifecore Biomedical, Inc. Reaffirms Earnings Guidance for the Calendar Year 2026 - marketscreener.com
LFCR: Revenue and profit declined, but cost cuts and new wins support strong long-term growth outlook - TradingView
Lifecore Biomedical, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Lifecore Biomedical Q2 Earnings Call Highlights - MarketBeat
Lifecore Biomedical, Inc. (LFCR) Q2 FY2026 earnings call transcript - Yahoo Finance
LFCR: Q2 revenue fell 6.2% to $34.2M, but new business wins and guidance reaffirmed - tradingview.com
Lifecore Biomedical Backs 2026 Adj EBITDA of $20.5M-$25M >LFCR - Moomoo
Lifecore Biomedical Q2 revenue falls to $34.2 million as loss widens - Quiver Quantitative
Lifecore Biomedical 2026: Revenue $34.17M, EPS ($0.19) — 10-Q Summary - TradingView
Lifecore Biomedical: Q2 Earnings Snapshot - marketscreener.com
Lifecore Biomedical (NASDAQ: LFCR) Q2 revenue slips as 2026 guidance reaffirmed - Stock Titan
Lifecore Biomedical Reports Financial Results for the - GlobeNewswire
LFCR: Q2 2026 delivered strong revenue, margin expansion, and robust pipeline growth - TradingView
Lifecore Biomedical Q2 FY26 net loss widens to $6.2 million; revenue falls 6.2% to $34.2 million - Bitget
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
LFCR Q1 2026 Earnings: Wider-than-Expected Loss Overshadows the QuarterDiluted EPS Report - vinanet.vn
Zacks Research Upgrades Lifecore Biomedical (NASDAQ:LFCR) to Hold - MarketBeat
Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026 - GlobeNewswire
Lifecore Biomedical (LFCR) Tests Resistance After a Modest UptickBull Flag - dars.gov.et
Lifecore Biomedical signs three new customer de... - Pluang
Lifecore Biomedical Signs Three New Customer Agreements - The Manila Times
Lifecore Biomedical Announces Three New Customer Agreements Spanning Late-Stage Regenerative Medicine and Early-Stage Development Programs - Quiver Quantitative
Lifecore Biomedical Inc (LFCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lifecore Biomedical Inc (LFCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lifecore Biomedical Inc Azioni (LFCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.56%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):